Published in CMAJ on October 28, 2003
Hypolipidemic and Antioxidant Capacity of Spirulina and Exercise | NCT02837666
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ (2007) 9.10
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Revisiting Rose: strategies for reducing coronary heart disease. BMJ (2006) 2.53
A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35
Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors. Can Fam Physician (2004) 2.18
Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ (2006) 2.03
How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia (2012) 1.89
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ (2008) 1.70
How evidence-based are the recommendations in evidence-based guidelines? PLoS Med (2007) 1.60
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag (2009) 1.59
Income-based drug coverage in British Columbia: the impact on access to medicines. Healthc Policy (2006) 1.59
Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. Can J Cardiol (2008) 1.59
One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ (2007) 1.55
The 2003 Canadian recommendations for dyslipidemia management: revisions are needed. CMAJ (2005) 1.49
NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis (2005) 1.37
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ (2006) 1.30
Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol (2005) 1.29
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag (2007) 1.15
A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ (2010) 1.09
Quality indicators for cardiovascular primary care. Can J Cardiol (2007) 1.09
Practice tips. Chart audits in my practice. Can Fam Physician (2006) 1.00
The analysis by Manuel and colleagues creates controversy with headlines, not data. CMAJ (2005) 0.97
Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol (2007) 0.97
Appropriateness of current thresholds for obesity-related measures among Aboriginal people. CMAJ (2007) 0.91
Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Can J Cardiol (2008) 0.91
To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc (2010) 0.91
Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. Cardiovasc Diabetol (2010) 0.91
Quality of care for First Nations and non-First Nations People with diabetes. Clin J Am Soc Nephrol (2013) 0.90
Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag (2008) 0.90
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. Can J Cardiol (2006) 0.87
Questioning the benefits of statins. CMAJ (2005) 0.86
Both serum apolipoprotein B and the apolipoprotein B/apolipoprotein A-I ratio are associated with carotid intima-media thickness. PLoS One (2013) 0.86
Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci (2011) 0.85
PROVE-IT proved it: lower is better--pro. Can J Cardiol (2006) 0.85
Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults. Cardiovasc Diabetol (2012) 0.85
How many cardiovascular events can be prevented with optimal management of high-risk Canadians? Can J Cardiol (2008) 0.84
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia? Can J Cardiol (2007) 0.83
A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol (2006) 0.82
Lipid profile of type 2 diabetic and hypertensive patients in the jamaican population. J Lab Physicians (2010) 0.81
Should cholesterol-lowering medications be available in Canada without a prescription? Can J Cardiol (2007) 0.81
Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol (2009) 0.80
Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Can J Cardiol (2006) 0.80
Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. J Appl Lab Med (2016) 0.79
Surveillance and treatment of dyslipidemia in the post-infarct patient: can a nurse-led management approach make a difference? Can J Cardiol (2006) 0.79
Dyslipidemia guidelines. CMAJ (2004) 0.78
Reaching target lipid levels and the natural history of diabetes mellitus in patients surviving acute coronary syndrome: A retrospective cohort study from a tertiary care outpatient clinic. Exp Clin Cardiol (2008) 0.77
Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. Br J Pharmacol (2010) 0.77
Current Drug Options for Raising HDL Cholesterol. Curr Treat Options Cardiovasc Med (2005) 0.77
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser (2006) 0.76
Is nutritional labeling associated with individual health? The effects of labeling-based awareness on dyslipidemia risk in a South Korean population. Nutr J (2016) 0.75
Quality indicators for the prevention of cardiovascular disease in primary care. Can Fam Physician (2010) 0.75
Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2007) 0.75
An evaluation of class effect. CMAJ (2006) 0.75
Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events. Can Fam Physician (2007) 0.75
Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. PLoS One (2011) 0.75
Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin. World J Cardiol (2009) 0.75
Does screening for peripheral arterial disease improve risk stratification for patients at intermediate risk for coronary artery disease? Open Med (2007) 0.75
Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model. Adv Prev Med (2010) 0.75
Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. Medicine (Baltimore) (2016) 0.75
The Canadian lipid guidelines are difficult to model quantitatively. Can J Cardiol (2008) 0.75
Dyslipidemia guidelines. CMAJ (2004) 0.75
Questioning the benefits of statins. CMAJ (2005) 0.75
The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Can J Cardiol (2006) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation (1999) 5.62
Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ (2000) 3.23
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (2004) 21.65
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
LDL-cholesterol concentrations: a genome-wide association study. Lancet (2008) 6.44
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation (2009) 3.98
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Results of the Ontario survey on the prevalence and control of hypertension. CMAJ (2008) 2.88
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ (2011) 2.34
Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med (2011) 2.29
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) (2009) 2.07
Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut (2011) 2.03
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med (2009) 1.85
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability. Sci Transl Med (2010) 1.75
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial Transplant (2007) 1.67
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol (2009) 1.64
Lack of MEF2A mutations in coronary artery disease. J Clin Invest (2005) 1.62
Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet (2011) 1.60
A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. Arterioscler Thromb Vasc Biol (2004) 1.59
Lack of support for the association between GAD2 polymorphisms and severe human obesity. PLoS Biol (2005) 1.59
Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. Can J Cardiol (2008) 1.59
Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? Clin Chem (2002) 1.55
The impact of dietary changes and dietary supplements on lipid profile. Can J Cardiol (2011) 1.54
The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol (2003) 1.52
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke (2013) 1.51
Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. Nephrol Dial Transplant (2007) 1.49
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol (2004) 1.47
Discordance between Framingham Risk Score and atherosclerotic plaque burden. Eur Heart J (2013) 1.46
Dietary measures and exercise training contribute to improvement of endothelial function and atherosclerosis even in patients given intensive pharmacologic therapy. J Cardiopulm Rehabil (2006) 1.44
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study. Atherosclerosis (2007) 1.36
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol (2005) 1.32
Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol (2011) 1.32
Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum Mol Genet (2008) 1.30
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
Galactose enhances oxidative metabolism and reveals mitochondrial dysfunction in human primary muscle cells. PLoS One (2011) 1.19
A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol (2013) 1.18
Age, gender, and urban-rural differences in the correlates of physical activity. Prev Med (2004) 1.15
Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). Am J Hypertens (2008) 1.15
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol (2011) 1.12
Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol (2012) 1.10
Decreased mitochondrial proton leak and reduced expression of uncoupling protein 3 in skeletal muscle of obese diet-resistant women. Diabetes (2002) 1.10
Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol (2011) 1.10
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics (2004) 1.08
Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis (2011) 1.08
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem (2003) 1.08
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol (2003) 1.07
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circ Res (2017) 1.06
Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol (2007) 1.06
Gene expression profiling in whole blood identifies distinct biological pathways associated with obesity. BMC Med Genomics (2010) 1.05
Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem (2003) 1.05
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol (2010) 1.05
Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol (2013) 1.03
Gain-of-function R225W mutation in human AMPKgamma(3) causing increased glycogen and decreased triglyceride in skeletal muscle. PLoS One (2007) 1.03
ERRgamma regulates cardiac, gastric, and renal potassium homeostasis. Mol Endocrinol (2009) 1.02
Distinct skeletal muscle fiber characteristics and gene expression in diet-sensitive versus diet-resistant obesity. J Lipid Res (2010) 1.01
Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol (2013) 1.01
Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation. J Lipid Res (2010) 1.00
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res (2011) 1.00
Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. J Lipid Res (2005) 1.00
The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort. Metabolism (2011) 0.97
The analysis by Manuel and colleagues creates controversy with headlines, not data. CMAJ (2005) 0.97